## **Artit Ungkanont**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11426780/publications.pdf

Version: 2024-02-01

1163117 1372567 12 263 8 10 citations h-index g-index papers 12 12 12 454 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021063.	1.3	1
2	Treatment outcome and prognostic factors in PCNSL. Diagnostic Pathology, 2019, 14, 56.	2.0	24
3	Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. Experimental Hematology and Oncology, 2019, 8, 3.	5.0	17
4	The use of hematocrit level for predicting the efficiency of peripheral blood <scp>CD</scp> 34 <sup>+</sup> cell collection after <scp>G</scp> â€ <scp>CSF</scp> Mobilization in Healthy Donors. Journal of Clinical Apheresis, 2015, 30, 329-334.	1.3	16
5	Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk Stratification. Biology of Blood and Marrow Transplantation, 2014, 20, 2066-2071.	2.0	43
6	Pretransplant Immunosuppression followed by Reduced-Toxicity Conditioning and Stem Cell Transplantation in High-Risk Thalassemia: A Safe Approach to Disease Control. Biology of Blood and Marrow Transplantation, 2013, 19, 1259-1262.	2.0	35
7	Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. American Journal of Hematology, 2007, 82, 1095-1098.	4.1	30
8	Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia. Biology of Blood and Marrow Transplantation, 2006, 12, 683-687.	2.0	55
9	Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leukemia Research, 2006, 30, 1493-1498.	0.8	36
10	Reduced Intensity Hematopoietic Stem Cell Transplantation for Treatment of Class 3 Lucarelli Severe Thalassemia Patients Blood, 2006, 108, 5364-5364.	1.4	O
11	Outcomes of Transplantation with Matched-Related Donor (MRD) and Alternative Donor (AD) Stem Cells in Children with Severe Thalassemia Blood, 2004, 104, 2160-2160.	1.4	O
12	Host Origin of Marrow Mesenchymal Stem Cells Following Allogeneic Cord-Blood Stem-Cell Transplantation. International Journal of Hematology, 2001, 74, 235-236.	1.6	6